LOCAL DRAFT · STAGING — NOT PUBLISHED
ONCOdianova® – The Future of Biomarkers
ENDE
● Contact

P·01 Products / Immune checkpoint

R12 — anti-CD112R/PVRIG for brightfield and multiplex IHC.

Clone R12 · Cat. no. DIA-R12 · Receptor CD112R/PVRIG, not the ligand CD112/NECTIN2

Scientific USP

523 colorectal cancers — peer-reviewed multiplex IHC

Yang 2023 · Modern Pathology · clone R12 / DIA-R12 named

  • CD112R/PVRIG receptor — not CD112/NECTIN2
  • Brightfield + multiplex · human FFPE
  • High signal-to-background

Publications — panel conditions as published (AR pH 7.8 · 1:500 · Opal 570).

Mouse monoclonal antibody for studying the inhibitory receptor CD112R (PVRIG) in human formalin-fixed, paraffin-embedded tissue. Documented for brightfield IHC and fluorescence multiplex IHC, with tonsil as positive control and a membranous lymphocyte staining pattern; clone R12 combines high specificity with an inherently high signal-to-background ratio and is well suited for multiplex IHC studies on human tissues. Clone R12 (DIA-R12) is named in the methods of a peer-reviewed multiplex study of 523 colorectal cancers and of a doctoral thesis on tumor and normal tissues.

View product dataOrderIHC galleryContact ↗
Evidence layer 01

Clone-specific datasheet

Datasheet DIA-R12 (version 25 Feb 2025/04; product content identical to V03, 22 Feb 2022) documents identity, immunogen, formulation, reconstitution, storage, FFPE-IHC starting conditions, tonsil control and membranous pattern. The datasheet is currently undergoing scientific correction and is not offered for download in this draft.

Evidence layer 02

Clone-specific publications

Yang et al., Modern Pathology 2023: fluorescence multiplex IHC on 523 colorectal cancers, antibody table names clone R12 / DIA-R12 (pH 7.8, 1:500, Opal 570). Jansen, doctoral thesis 2020/2021: multiplex IHC on 122 tumors and 17 normal tissues with DIA-R12; specificity examined by Western blot, ELISA and pre-absorption.

Evidence layer 03

Documented applications and images

Brightfield IHC and fluorescence multiplex IHC on human FFPE tissue; 15 original ONCOdianova figures (brightfield, CD112R × CD8, CD112R × FOXP3), a manual protocol and the published multiplex conditions. No comparative or diagnostic claim is made.

Brightfield and multiplex gallery: section P·03 ↓

P·02 Technical data

Clone R12 technical specifications.

ProductAnti-CD112R/PVRIG (Human) from Mouse
CloneR12 (monoclonal)
Catalog numberDIA-R12
Distributor catalog numberODN-DIA-R12 (BIOZOL)
TargetCD112R / PVRIG — poliovirus receptor-related immunoglobulin domain-containing protein, the CD112 receptor (Gene ID 79037, UniProt Q6DKI7). Not the ligand CD112/NECTIN2/PVRL2.
ImmunogenRecombinant peptide (sequence, region and epitope not published)
IsotypeMouse IgG1/κ
Host speciesMouse
ReactivityHuman
ConjugationUnconjugated
Format100 µl, lyophilized; antibody purified from culture supernatant
ReconstitutionRestore to 100 µl with sterile distilled water; gentle shaking for 10 minutes
FormulationPBS, pH 7.4, 2% BSA, 0.05% sodium azide
ApplicationsIHC on standard FFPE sections (datasheet) · fluorescence multiplex IHC (datasheet reactivity text; clone-specific publications; gallery) · Western blot specificity check of DIA-R12 reported in the Jansen thesis
IHC starting range1:100 – 1:200 for polymer-based detection (datasheet); 1:150 in the manual protocol of the previous product page; optimal dilution to be determined by the user for tissue, fixation, platform and detection system
Epitope retrievalHeat-induced epitope retrieval required; autoclave 121 °C, 5 min, Tris-EDTA-citrate pH 7.8 recommended
Primary antibody incubation60 min at 37 °C (datasheet and previous product page)
Positive controlTonsil
Staining patternMembranous (lymphocyte subsets)
Automated platformsSuited for automated IHC platforms (datasheet)
StorageLyophilized at 2–8 °C; long-term at −20 °C (stable for at least one year); reconstituted at 2–8 °C short term (several weeks); avoid repeated freeze/thaw cycles
Associated antibodiesDIA-TC8 (anti-CD8, clone TC8) · DIA-TG1 (anti-TIGIT, clone TG1) — as listed in the datasheet; each clone carries its own evidence
StatusResearch Use Only

The technical specifications above are documented in datasheet DIA-R12 (version 25 Feb 2025/04), whose product content is identical to V03 (22 Feb 2022), and on the previous ONCOdianova product page where indicated; gene and protein entries link to their registries. The ligand CD112/NECTIN2 is named only to distinguish it from the target. Each laboratory must validate its own conditions.

P·04 Documented protocols

Positive control and IHC protocol for clone R12.

Three sources, three scopes. Block A is the current datasheet and the starting point for in-house establishment. Block B is the manual protocol of the previous ONCOdianova product page. Block C shows the multiplex conditions reported in the clone-specific studies – they belong to the respective study panel and are not a general recommendation for use. Dilutions are starting values; each laboratory validates tissue, fixation, platform and detection itself.

A · DatasheetImmunohistochemical staining of standard formalin-fixed paraffin sectionsDatasheet DIA-R12 · version 25 Feb 2025/04 (identical wording in V03, 22 Feb 2022)

Preparation and epitope retrieval

  1. Deparaffinize and rehydrate according to standard procedures
  2. Heat-induced epitope retrieval (HIER) is required
  3. Recommended: autoclave at 121 °C (5 min) in Tris-EDTA-citrate, pH 7.8 (e.g. TEC buffer)

Primary antibody and detection

  1. Incubate primary antibody for 60 min at 37 °C
  2. Biotin/(strept)avidin-based detection possible (e.g. Vectastain® Elite® ABC-HRP kit/AEC)
  3. Polymer-based detection (e.g. Dako EnVision™ detection system, peroxidase/DAB): antibody at 1:100–1:200
  4. Suited for automated staining platforms (datasheet)
  5. Run positive and negative controls in parallel; positive control: tonsil; expected pattern: membranous
B · Previous product pageManual stain with autoclaveONCOdianova product page DIA-R12, section “IHC protocols” (as of 29 Aug 2026)
  1. Reconstitution: restore DIA-R12 to 100 µl with sterile distilled water, gentle shaking for 10 minutes
  2. Pretreatment buffer: 121 °C / 5 min / pH 7.8
  3. Incubation primary antibody: 60 min / 37 °C, dilution 1:150
  4. EnVision HRP rabbit/mouse: 30 min / 37 °C

The previous page added: “Applicable for automated staining procedures and validated for multicolor immunofluorescence (multiplexed IHC)”. Suitability for automated procedures is also stated in the datasheet; the multiplex application is documented by the clone-specific studies (block C) and the gallery. The 1:150 dilution lies within the datasheet range of 1:100–1:200.

C · Published study conditionsFluorescence multiplex IHC with DIA-R12 (study context, not a recommendation for use)Yang et al., Mod Pathol 2023, Table 1 · Jansen, doctoral thesis UKE 2020/2021, section 2.3

Yang et al. 2023 (523 colorectal cancers, TMA and large sections)

  1. Freshly cut 4-µm consecutive sections; Opal Dye Kit (Akoya Biosciences, Cat. #NEL811001KT)
  2. CD112R: Dianova, clone R12, Cat# DIA-R12 · antigen retrieval pH 7.8 · dilution 1:500 · staining position 2 · Opal 570
  3. Other panel markers of the study: Ki67 (position 1), PD-1 (position 3), CD8 (position 4) – reagents of other manufacturers, see publication
  4. Image acquisition: Leica Aperio VERSA 8 epifluorescence scanner; deep learning–based cell segmentation

Jansen 2020/2021 (122 tumors from seven entities, 17 normal tissues)

  1. 4-µm consecutive sections of 4-mm microenvironment TMAs and large sections; OPAL Dye Kit (Perkin Elmer, Cat. #OP7DS1001KT) following the Akoya protocol
  2. Epitope retrieval in an autoclave for 30 min at 100–120 °C in buffer pH 9 (protocol of the thesis); antibody stripping in the microwave (5 min 100 °C, 5 min 93 °C) between cycles; DAPI counterstain
  3. Anti-CD112R clone DIA-R12 (Dianova, Hamburg); specificity examined in the thesis by Western blot, ELISA and pre-absorption with CD112R protein; membranous staining pattern reported

The 1:500 dilution and the Opal panel position apply to the described multiplex protocol and do not replace the datasheet starting range of 1:100–1:200 for brightfield IHC. The thesis lists the R12 dilution in its antibody table (Table 1, embedded as an image in the full text); it is not transferred here.

P·05 Interpretation guide

How to read the staining.

Expected pattern

Membranous, lymphocyte subsets

The datasheet describes a membranous pattern with tonsil as positive control. In the published studies with DIA-R12, CD112R signal was reported at variable intensity on CD8+, CD4+, FOXP3+ and CD56+ cells but not on CD11c+ dendritic cells or CD68+ macrophages (Jansen 2020/2021), and was elevated on CD8+ T cells within T-cell nests of colorectal cancer (Yang 2023). These are study results in the respective cohorts, not a general expression map.

Documented validation scope

High signal-to-noise CD112R detection in human tissue

Clone R12 was validated for sensitivity and specificity on a large number of normal and tumor tissues and showed no background staining in non-lymphoid and epithelial cells. It combines high specificity with an inherently high signal-to-background ratio, well suited for multiplex IHC studies. The Jansen thesis reports that DIA-R12 was examined by Western blot, ELISA and pre-absorption of the primary antibody with CD112R protein before multiplex use, and describes a consistently membranous pattern; Yang 2023 used DIA-R12 in a peer-reviewed multiplex panel.

Scope of evidence

Documented evidence scope

The documented evidence for R12 consists of product datasheet DIA-R12, the previous ONCOdianova product page and gallery, one peer-reviewed multiplex study naming DIA-R12 (Yang 2023) and one doctoral thesis naming DIA-R12 (Jansen 2020/2021). Two AACR 2020 congress abstracts of the same group are listed as such. No claim of superiority over other antibodies and no diagnostic, prognostic or therapeutic claim is made. For research use only.

P·06 Target background

CD112R/PVRIG in research.

CD112R, also called PVRIG (poliovirus receptor-related immunoglobulin domain-containing protein; gene PVRIG, formerly C7orf15), is a transmembrane receptor of the poliovirus receptor/nectin family. It was identified as a coinhibitory receptor on human T cells that binds CD112 (nectin-2) with high affinity and competes with the costimulatory receptor CD226 (DNAM-1) for this ligand; disrupting the CD112R–CD112 interaction enhanced human T-cell responses in vitro.[1]

CD112 is broadly expressed on antigen-presenting cells and on tumor cells. PVRIG and its ligand PVRL2/CD112 are induced in cancer and inhibit CD8+ T-cell function,[4] and blockade of CD112R together with TIGIT sensitizes human NK-cell functions.[3] Together with TIGIT, CD226, CD96 and their ligands CD155 (PVR) and CD112, CD112R forms a receptor–ligand network that is studied as an immune checkpoint axis in cancer.[2, 5]

These statements describe the target. They are not evidence for the analytical performance of clone R12 and do not establish which cell populations R12 detects in a given specimen. Clone R12 is a research tool for tissue-based CD112R/PVRIG studies; it carries no diagnostic or therapeutic claim.

  • GenePVRIG — NCBI Gene 79037
  • ProteinTransmembrane protein PVRIG / CD112 receptor — UniProt Q6DKI7
  • AliasesCD112R · PVRIG · C7orf15
  • LigandCD112 (nectin-2; gene NECTIN2, formerly PVRL2) — a different protein, not detected by R12
  • Competing receptorCD226 (DNAM-1) — Zhu et al. 2016 [1]
  • Related axisTIGIT / CD226 / CD96 with CD155 (PVR) and CD112 — see the ONCOdianova anti-TIGIT clones TG1 and TG2

Bracketed numbers refer to the target-literature list below. Target biology is kept separate from clone-specific product claims.

P·07 Publications

Documented evidence.

Clone-specific evidence (clone R12 / DIA-R12 named in the source text)

  1. Yang C, Mandelkow T, Bady E, Raedler JB, Simon R, Sauter G, Lennartz M, Büscheck F, Luebke AM, Dum D, Menz A, Höflmayer D, Weidemann S, Fraune C, Lebok P, Uhlig R, Bernreuther C, Jacobsen F, Clauditz TS, Wilczak W, Minner S, Burandt E, Steurer S, Blessin NC. Nonredundant Upregulation of CD112R (PVRIG) and PD-1 on Cytotoxic T Lymphocytes Located in T Cell Nests of Colorectal Cancer. Modern Pathology (2023); 36(4):100089. doi:10.1016/j.modpat.2022.100089 · PMID 36788088
    Fluorescence multiplex IHC (CD8, PD-1, CD112R, Ki67) on FFPE tissue microarrays and large sections of 523 colorectal cancers with follow-up; R12 at antigen retrieval pH 7.8, 1:500, staining position 2, Opal 570.    Peer-reviewed article · clone R12 / DIA-R12 named in Table 1
  2. Jansen HL. Expressionsunterschiede des Immuncheckpoint-Rezeptors CD112R in humanen Karzinomen im Vergleich zu Normalgeweben. Doctoral thesis, University of Hamburg / Institute of Pathology, University Medical Center Hamburg-Eppendorf (2020 (accepted 27 Jul 2021)); URN urn:nbn:de:gbv:18-ediss-94757. Repository (University of Hamburg)
    Fluorescence multiplex IHC on 4-mm microenvironment TMAs of 122 tumors (seven entities) and large sections of 17 normal tissues; CD112R examined on CD8+, CD4+, FOXP3+, CD56+, CD11c+ and CD68+ cells; specificity of DIA-R12 examined by Western blot, ELISA and pre-absorption with CD112R protein.    Academic thesis · clone DIA-R12 named in section 2.3

Congress abstracts listed on the previous ONCOdianova product page

  1. Blessin NC, Mandelkow T, Bady E, Hube-Magg C, Sauter G, Simon R, Fraune C, Lennartz M, Weidemann SA, Möller K, Höflmayer D. Abstract 3870: Patterns of CD112R expression in normal lymphatic tissues, inflammation and cancer. Cancer Research (2020); 80(16 Suppl): 3870. doi:10.1158/1538-7445.AM2020-3870Congress abstract · AACR 2020
  2. Simon R, Blessin NC, Mandelkow T, Bady E, Hube-Magg C, Sauter G, Lennartz M, Fraune C, Weidemann SA, Möller K, Büscheck F. Abstract 4970: Prognostic role of CD112R, PD-1 and Ki67 expression in CD8+cytotoxic T cells in colorectal cancer. Cancer Research (2020); 80(16 Suppl): 4970. doi:10.1158/1538-7445.AM2020-4970Congress abstract · AACR 2020

The previous ONCOdianova page listed both abstracts as “specific references”. Their published abstract text describes CD112R multiplex IHC by the same Hamburg group that later published Yang et al. 2023.

Target literature cited in the datasheet

  1. Zhu Y et al. Identification of CD112R as a novel checkpoint for human T cells. Journal of Experimental Medicine (2016). doi:10.1084/jem.20150785 · PMID 26755705Target biology
  2. Stamm H, Wellbrock J, Fiedler W. Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. Mammalian Genome (2018). doi:10.1007/s00335-018-9770-7 · PMID 30132062Target biology · review
  3. Xu F et al. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunology, Immunotherapy (2017). doi:10.1007/s00262-017-2031-x · PMID 28623459Target biology
  4. Whelan S et al. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function. Cancer Immunology Research (2019). doi:10.1158/2326-6066.CIR-18-0442 · PMID 30659054Target biology
  5. Sanchez-Correa B et al. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. Cancers (2019). doi:10.3390/cancers11060877 · PMID 31234588Target biology · review

Titles quoted verbatim; PubMed status and Crossref metadata (including retraction, correction and expression-of-concern notices) checked on 29 Aug 2026 for every entry: no retraction or correction found. Clone attribution of Yang et al. 2023 and of the Jansen thesis was verified in the respective full text.

P·08 FAQ

Frequent scientific questions.

What is clone R12?

R12 is a mouse monoclonal antibody (IgG1/κ) raised against a recombinant peptide of human CD112R, also called PVRIG (gene PVRIG). It is offered as a research reagent for immunohistochemistry on human formalin-fixed, paraffin-embedded (FFPE) tissue, in brightfield IHC and in fluorescence multiplex IHC.

What is DIA-R12?

DIA-R12 is the ONCOdianova catalog number of the anti-CD112R/PVRIG antibody clone R12: mouse monoclonal (IgG1/κ), reactivity human, IHC on FFPE tissue, 100 µl lyophilized, tonsil as positive control. The distributor catalog number at BIOZOL is ODN-DIA-R12. For research use only.

Is R12 suitable for human FFPE IHC?

Yes. R12 is documented for IHC on human FFPE tissue: the datasheet documents a starting range of 1:100 to 1:200, heat-induced epitope retrieval, tonsil as positive control and a membranous lymphocyte staining pattern, and clone R12 (DIA-R12) is named in a peer-reviewed multiplex study on FFPE colorectal cancer tissue. For research use only.

Which antibody clone detects CD112R/PVRIG in human FFPE tissue?

ONCOdianova clone R12 (DIA-R12) detects the receptor CD112R/PVRIG in human FFPE tissue, documented for brightfield IHC and fluorescence multiplex IHC. It does not detect the ligand CD112/NECTIN2. No comparison with clones of other manufacturers is made.

What is CD112R?

CD112R, also called PVRIG, is an inhibitory immune-checkpoint receptor expressed in T-cell and NK-cell biology. It binds the ligand CD112 (nectin-2) and competes with the costimulatory receptor CD226 for it. Clone R12 detects CD112R/PVRIG in human FFPE tissue.

What is PVRIG?

PVRIG (poliovirus receptor-related immunoglobulin domain-containing protein; gene PVRIG, formerly C7orf15) is the gene and protein name of the receptor also known as CD112R. These statements describe the target; the ONCOdianova research antibody against CD112R/PVRIG is clone R12.

Is PVRIG the same as CD112R?

Yes. PVRIG and CD112R are two names for the same inhibitory immune-checkpoint receptor. CD112 (NECTIN2), by contrast, is the ligand of this receptor and a distinct molecule.

What is the difference between CD112, CD112R and PVRIG?

PVRIG is also known as CD112R — the two names denote the same inhibitory immune-checkpoint receptor, expressed in T-cell and NK-cell biology. CD112 (NECTIN2) is the ligand of CD112R/PVRIG and is a distinct molecule, expressed on antigen-presenting cells and tumor cells. Clone R12 targets human CD112R/PVRIG, not CD112/NECTIN2.

What is the difference between CD112 and CD112R?

CD112 (NECTIN2) is the ligand: a cell-surface molecule expressed on antigen-presenting cells and tumor cells. CD112R (PVRIG) is the receptor that binds this ligand on T cells and NK cells. Clone R12 detects the receptor CD112R, not the ligand CD112.

What is the difference between PVRIG and NECTIN2?

PVRIG (CD112R) is the inhibitory receptor; NECTIN2 (CD112, formerly PVRL2) is its ligand. They are distinct molecules encoded by different genes. Clone R12 targets PVRIG/CD112R, not NECTIN2/CD112.

Does R12 target CD112 or CD112R?

Clone R12 targets human CD112R (PVRIG), the receptor. It does not target CD112 (NECTIN2), the ligand.

Is CD112 the ligand of CD112R/PVRIG?

Yes. CD112 (nectin-2; gene NECTIN2, formerly PVRL2) is the ligand of the receptor CD112R/PVRIG and is a distinct molecule that is not detected by clone R12.

Are there peer-reviewed publications using clone R12?

Yes. Yang et al., Modern Pathology 2023 (PMID 36788088) name clone R12 and catalog number DIA-R12 in their antibody table and used the antibody in fluorescence multiplex IHC on 523 colorectal cancers. The doctoral thesis of Jansen (University of Hamburg, 2020/2021) names DIA-R12 in its methods. Both were verified in the full text on 29 August 2026.

Is R12 used in multiplex immunohistochemistry?

Yes. Clone R12 (DIA-R12) is named in a peer-reviewed fluorescence multiplex IHC study of 523 colorectal cancers (Yang et al., Modern Pathology 2023) and in the multiplex methods of a doctoral thesis (Jansen 2020/2021), and ONCOdianova gallery images document CD112R × CD8 and CD112R × FOXP3 multiplex staining.

Is R12 used in multiplex immunofluorescence?

Yes. The published use of DIA-R12 is fluorescence-based multiplex IHC: Yang et al. 2023 used the antibody within an Opal panel (antigen retrieval pH 7.8, 1:500, Opal 570) on FFPE tissue. Published conditions are study-specific and must be re-optimized for other systems.

Can R12 be combined with CD8 in a multiplex panel?

A published fluorescence multiplex panel combined CD112R (clone R12), CD8, PD-1 and Ki67 on FFPE colorectal cancer tissue (Yang et al. 2023), and ONCOdianova images show CD112R × CD8 multiplex staining of tonsil. Every new panel must be verified for tissue, antibody order, retrieval, dilution and detection.

What is the recommended dilution for R12 IHC?

The datasheet states 1:100 to 1:200 for polymer-based peroxidase/DAB detection on FFPE sections; the previous product page used 1:150 in its manual protocol. The published multiplex study used 1:500 within an Opal panel – a study-specific condition. The optimal dilution must be determined by the user for each tissue, fixation, platform and detection system.

Which epitope retrieval does R12 require?

Heat-induced epitope retrieval is required. The datasheet recommends an autoclave at 121 °C for 5 minutes in Tris-EDTA-citrate buffer, pH 7.8 (TEC buffer). The published multiplex study also used antigen retrieval at pH 7.8 for the R12 step.

What positive control tissue is documented for R12?

Tonsil is listed as a positive-control tissue for clone R12, with a membranous staining pattern of lymphocyte subsets. The gallery includes CD112R × CD8 and CD112R × FOXP3 multiplex images of normal human tonsil.

Has R12 been validated for sensitivity and specificity?

Yes. Clone R12 has been validated for sensitivity and specificity in human tissue IHC applications, across a large number of normal and tumor tissues.

Does R12 have a high signal-to-noise ratio?

Clone R12 combines high specificity with an inherently high signal-to-background ratio, making it well suited for multiplex IHC studies on human tissues. No comparison with other manufacturers’ clones is made.

What is known about background staining with clone R12?

In ONCOdianova validation, clone R12 showed no background staining in non-lymphoid and epithelial cells. This statement applies to the documented validation context and is not a claim of universal background-free staining in every tissue or protocol.

Can R12 be used for Western blot?

The doctoral thesis of Jansen reports that the specificity of DIA-R12 was examined by Western blot, ELISA and pre-absorption with CD112R protein.

What is the documented validation scope of clone R12?

Clone R12 was validated for sensitivity and specificity on a large number of normal and tumor tissues and showed no background staining in non-lymphoid and epithelial cells; it combines high specificity with an inherently high signal-to-background ratio, making it well suited for multiplex IHC studies on human tissues. Independently published clone-specific evidence includes brightfield IHC and fluorescence multiplex IHC on human FFPE tissue (Yang 2023; Jansen 2020/2021), including the Western blot, ELISA and pre-absorption checks reported in the Jansen thesis.

Can R12 be used on automated staining platforms?

The datasheet states that the antibody is suited for immunohistochemical staining on automated platforms, and the previous product page stated that the protocol is applicable to automated staining procedures.

What is the role of PVRIG in T cells and NK cells?

CD112R/PVRIG is a coinhibitory receptor on human T cells and NK cells. It binds CD112 (nectin-2) with high affinity, competes with the costimulatory receptor CD226 (DNAM-1) for this ligand, and its blockade — alone or together with TIGIT — enhanced T-cell and NK-cell functions in published in-vitro studies. These statements describe target biology; they are not performance evidence for clone R12.

Is R12 intended for diagnostic use?

No. R12 is intended for research use only and is not intended for diagnostic or therapeutic procedures.

P·09 Documents

Ordering and catalogue information.

Datasheet

DIA-R12

The datasheet for DIA-R12 is undergoing scientific correction and is therefore not offered for download in this local draft. A corrected, newly versioned datasheet will be provided here after its release by ONCOdianova.

PDF · in scientific correction · not available at present

IHC gallery

CD112R IHC gallery

The “CD112R IHC-Gallery” of the previous website is integrated in section P·03 of this page with 15 figures and their legends.

Go to gallery ↓

15 figures · brightfield and multiplex

Safety

MSDS

Material safety data sheet (ONCOdianova, all lyophilized antibodies).

Download PDF ↓

PDF · V02 · 216 KB

Ordering. ONCOdianova products are purchased through our distribution partner BIOZOL Diagnostica Vertrieb GmbH, Oehleckerring 11–13, 22419 Hamburg, Germany — order requests by e-mail: order@biozol.de (CC info@oncodianova.com). See also order information and distributors (in preparation).

The technical data on this page are taken from datasheet DIA-R12 (version 25 Feb 2025/04; product content identical to V03, 22 Feb 2022). The datasheet is undergoing scientific correction; a corrected, newly versioned datasheet requires release by ONCOdianova before it is offered here. Related: TG1 (anti-TIGIT) · TG2 (anti-TIGIT) · KK3 (CD73/NT5E) · TC8 (CD8) · FX3 (FOXP3).

For Research Use Only. Not for diagnostic or therapeutic use.